Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02PBY
|
||||
| Former ID |
DNC006933
|
||||
| Drug Name |
3-noradamantyl-1,3-dipropylxanthine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528544] | ||
| Formula |
C20H28N4O2
|
||||
| Canonical SMILES |
CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CC5CC(C3)C(C5)C4
|
||||
| InChI |
1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-9-12-7-13(10-20)14(8-12)11-20/h12-14H,3-11H2,1-2H3,(H,21,22)
|
||||
| InChIKey |
IDHJABAMUQNMKF-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [528544] | |
| Adenosine A2b receptor | Target Info | Inhibitor | [528544] | ||
| Adenosine A2a receptor | Target Info | Inhibitor | [528544] | ||
| Adenosine A3 receptor | Target Info | Inhibitor | [528544] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholismhsa04015:Rap1 signaling pathway | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.